Alkem Labs Board Approves FY26 Results, Recommends ₹10 Dividend, Reappoints Director
Alkem Laboratories approved FY26 audited financial results and recommended a final dividend of ₹10 per share. The 52nd AGM is scheduled for August 27, 2026. Mrs. Madhurima Singh was re-appointed as Executive Director for five years from December 20, 2026.
The declaration of dividend and re-appointment of a director are material events for shareholders and stakeholders, impacting investor sentiment and corporate governance.
The company reported positive financial results and recommended a dividend, alongside a significant management re-appointment, indicating stability and confidence.
Alkem Laboratories Limited announced the outcome of its Board Meeting held on May 28, 2026. The Board has approved the Audited Financial Results for the quarter and financial year ended March 31, 2026, both on a standalone and consolidated basis.
The Board has recommended a final dividend of ₹10 per equity share of ₹2 each for the financial year ended March 31, 2026. This recommendation is subject to the approval of shareholders at the upcoming Annual General Meeting (AGM).
The 52nd AGM of the Company has been scheduled for August 27, 2026, with a cut-off date for the AGM set as August 20, 2026. Additionally, August 07, 2026, has been fixed as the record date for the payment of the final dividend, which, if declared, will be paid on or after September 01, 2026.
Furthermore, based on the recommendations of the Nomination and Remuneration Committee and the Audit Committee, and subject to shareholder approval at the AGM, the Board has approved the re-appointment of Mrs. Madhurima Singh as an Executive Director for a term of five consecutive years, effective from December 20, 2026, to December 19, 2031.
The auditors have expressed an unmodified opinion in the Audit Reports on the financial results. The Board meeting commenced at 11:20 a.m. and concluded at 01:15 p.m.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.